BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yun HM, Oh JH, Shim JH, Ban JO, Park KR, Kim JH, Lee DH, Kang JW, Park YH, Yu D, Kim Y, Han SB, Yoon DY, Hong JT. Antitumor activity of IL-32β through the activation of lymphocytes, and the inactivation of NF-κB and STAT3 signals. Cell Death Dis 2013;4:e640. [PMID: 23703385 DOI: 10.1038/cddis.2013.166] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 4.2] [Reference Citation Analysis]
Number Citing Articles
1 Jung YY, Katila N, Neupane S, Shadfar S, Ojha U, Bhurtel S, Srivastav S, Son DJ, Park PH, Yoon DY, Hong JT, Choi DY. Enhanced dopaminergic neurotoxicity mediated by MPTP in IL-32β transgenic mice. Neurochem Int 2017;102:79-88. [PMID: 27956238 DOI: 10.1016/j.neuint.2016.12.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
2 Yan H, He D, Huang X, Zhang E, Chen Q, Xu R, Liu X, Zi F, Cai Z. Role of interleukin-32 in cancer biology. Oncol Lett 2018;16:41-7. [PMID: 29930712 DOI: 10.3892/ol.2018.8649] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
3 Semango G, Heinhuis B, Plantinga TS, Blokx WAM, Kibiki G, Sonda T, Mavura D, Masenga EJ, Nyindo M, van der Ven AJAM, Joosten LAB. Exploring the Role of IL-32 in HIV-Related Kaposi Sarcoma. Am J Pathol 2018;188:196-203. [PMID: 29037857 DOI: 10.1016/j.ajpath.2017.08.033] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
4 Pavlovic M, Gajovic N, Jurisevic M, Mitrovic S, Radosavljevic G, Pantic J, Arsenijevic N, Jovanovic I. Diverse Expression of IL-32 in Diffuse and Intestinal Types of Gastric Cancer. Gastroenterol Res Pract 2018;2018:6578273. [PMID: 30402092 DOI: 10.1155/2018/6578273] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
5 Lin X, Yang L, Wang G, Zi F, Yan H, Guo X, Chen J, Chen Q, Huang X, Li Y, Zhang E, Wu W, Yang Y, He D, He J, Cai Z. Interleukin-32α promotes the proliferation of multiple myeloma cells by inducing production of IL-6 in bone marrow stromal cells. Oncotarget 2017;8:92841-54. [PMID: 29190960 DOI: 10.18632/oncotarget.21611] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 3.4] [Reference Citation Analysis]
6 Song X, Wang D, Ben B, Xiao C, Bai L, Xiao H, Zhang W, Li W, Jia J, Qi Y. Association between interleukin gene polymorphisms and susceptibility to gastric cancer in the Qinghai population. J Int Med Res 2021;49:3000605211004755. [PMID: 33942631 DOI: 10.1177/03000605211004755] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
7 Han S, Yang Y. Interleukin-32: Frenemy in cancer? BMB Rep 2019;52:165-74. [PMID: 30638183 [PMID: 30638183 DOI: 10.5483/bmbrep.2019.52.3.019] [Cited by in Crossref: 7] [Article Influence: 2.3] [Reference Citation Analysis]
8 Yong HJ, Park JS, Lee Jeong A, Han S, Lee S, Ka HI, Sumiyasuren B, Joo HJ, So SJ, Park JY, Yoon DY, Lim JS, Lee MS, Lee HG, Yang Y. Von Hippel-Lindau regulates interleukin-32β stability in ovarian cancer cells. Oncotarget 2017;8:69833-46. [PMID: 29050245 DOI: 10.18632/oncotarget.19311] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
9 Pham TH, Bak Y, Kwon T, Kwon SB, Oh JW, Park JH, Choi YK, Hong JT, Yoon DY. Interleukin-32θ inhibits tumor-promoting effects of macrophage-secreted CCL18 in breast cancer. Cell Commun Signal 2019;17:53. [PMID: 31126309 DOI: 10.1186/s12964-019-0374-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
10 Yun HM, Kim JA, Hwang CJ, Jin P, Baek MK, Lee JM, Hong JE, Lee SM, Han SB, Oh KW, Choi DY, Yoon DY, Hong JT. Neuroinflammatory and Amyloidogenic Activities of IL-32β in Alzheimer's Disease. Mol Neurobiol 2015;52:341-52. [PMID: 25159479 DOI: 10.1007/s12035-014-8860-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
11 Lee DH, Hong JE, Yun HM, Hwang CJ, Park JH, Han SB, Yoon DY, Song MJ, Hong JT. Interleukin-32β ameliorates metabolic disorder and liver damage in mice fed high-fat diet. Obesity (Silver Spring) 2015;23:615-22. [PMID: 25645248 DOI: 10.1002/oby.21001] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
12 Erkasap N, Özyurt R, Özkurt M, Yaşar F, Erkasap S, Ihtiyar E. The role of JAK/STAT signaling pathway and TNF-α crosstalk in human colorectal cancer. Gene Reports 2016;3:1-4. [DOI: 10.1016/j.genrep.2016.01.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
13 Li W, Deng W, Xie J. The Biology and Role of Interleukin-32 in Tuberculosis. J Immunol Res 2018;2018:1535194. [PMID: 30426023 DOI: 10.1155/2018/1535194] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
14 Feng C, Bai M, Zhang H, Zeng A, Zhang W. Prioritization and comprehensive analysis of genes associated with melanoma. Oncol Lett 2019;18:127-36. [PMID: 31289481 DOI: 10.3892/ol.2019.10284] [Reference Citation Analysis]
15 Gong L, Dong C, Cai Q, Ouyang W. Interleukin 32: A novel player in perioperative neurocognitive disorders. Med Hypotheses 2020;144:110158. [PMID: 33254483 DOI: 10.1016/j.mehy.2020.110158] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
16 Park MH, Yoon DY, Ban JO, Kim DH, Lee DH, Song S, Kim Y, Han SB, Lee HP, Hong JT. Decreased severity of collagen antibody and lipopolysaccharide-induced arthritis in human IL-32β overexpressed transgenic mice. Oncotarget 2015;6:38566-77. [PMID: 26497686 DOI: 10.18632/oncotarget.6160] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
17 Sloot YJE, Smit JW, Joosten LAB, Netea-Maier RT. Insights into the role of IL-32 in cancer. Semin Immunol 2018;38:24-32. [PMID: 29747940 DOI: 10.1016/j.smim.2018.03.004] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 6.0] [Reference Citation Analysis]
18 Yang Y, Wang Z, Zhou Y, Wang X, Xiang J, Chen Z. Dysregulation of over-expressed IL-32 in colorectal cancer induces metastasis. World J Surg Oncol 2015;13:146. [PMID: 25889282 DOI: 10.1186/s12957-015-0552-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
19 Sloot YJE, Rabold K, Ulas T, De Graaf DM, Heinhuis B, Händler K, Schultze JL, Netea MG, Smit JWA, Joosten LAB, Netea-maier RT. Interplay between thyroid cancer cells and macrophages: effects on IL-32 mediated cell death and thyroid cancer cell migration. Cell Oncol 2019;42:691-703. [DOI: 10.1007/s13402-019-00457-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
20 Lee YS, Lee CH, Bae JT, Nam KT, Moon DB, Hwang OK, Choi JS, Kim TH, Jun HO, Jung YS, Hwang DY, Han SB, Yoon DY, Hong JT. Inhibition of skin carcinogenesis by suppression of NF-κB dependent ITGAV and TIMP-1 expression in IL-32γ overexpressed condition. J Exp Clin Cancer Res 2018;37:293. [PMID: 30486830 DOI: 10.1186/s13046-018-0943-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
21 Gruber T, Kremenovic M, Sadozai H, Rombini N, Baeriswyl L, Maibach F, Modlin RL, Gilliet M, von Werdt D, Hunger RE, Seyed Jafari SM, Parisi G, Abril-Rodriguez G, Ribas A, Schenk M. IL-32γ potentiates tumor immunity in melanoma. JCI Insight 2020;5:138772. [PMID: 32841222 DOI: 10.1172/jci.insight.138772] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
22 Ma Z, Dong Z, Yu D, Mu M, Feng W, Guo J, Cheng B, Guo J, Ma J. IL-32 Promotes the Radiosensitivity of Esophageal Squamous Cell Carcinoma Cell through STAT3 Pathway. Biomed Res Int 2021;2021:6653747. [PMID: 33681363 DOI: 10.1155/2021/6653747] [Reference Citation Analysis]
23 Matondo M, Marcellin M, Chaoui K, Bousquet-Dubouch MP, Gonzalez-de-Peredo A, Monsarrat B, Burlet-Schiltz O. Determination of differentially regulated proteins upon proteasome inhibition in AML cell lines by the combination of large-scale and targeted quantitative proteomics. Proteomics 2017;17. [PMID: 27709814 DOI: 10.1002/pmic.201600089] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
24 Savoy RM, Chen L, Siddiqui S, Melgoza FU, Durbin-Johnson B, Drake C, Jathal MK, Bose S, Steele TM, Mooso BA, D'Abronzo LS, Fry WH, Carraway KL 3rd, Mudryj M, Ghosh PM. Transcription of Nrdp1 by the androgen receptor is regulated by nuclear filamin A in prostate cancer. Endocr Relat Cancer 2015;22:369-86. [PMID: 25759396 DOI: 10.1530/ERC-15-0021] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.9] [Reference Citation Analysis]
25 Yan H, Dong M, Liu X, Shen Q, He D, Huang X, Zhang E, Lin X, Chen Q, Guo X, Chen J, Zheng G, Wang G, He J, Yi Q, Cai Z. Multiple myeloma cell-derived IL-32γ increases the immunosuppressive function of macrophages by promoting indoleamine 2,3-dioxygenase (IDO) expression. Cancer Lett 2019;446:38-48. [PMID: 30660652 DOI: 10.1016/j.canlet.2019.01.012] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
26 Paz H, Tsoi J, Kalbasi A, Grasso CS, McBride WH, Schaue D, Butterfield LH, Maurer DM, Ribas A, Graeber TG, Economou JS. Interleukin 32 expression in human melanoma. J Transl Med 2019;17:113. [PMID: 30953519 DOI: 10.1186/s12967-019-1862-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
27 Lee YS, Han S, Ham HJ, Park JH, Lee JS, Hwang DY, Jung YS, Yoon DY, Hong JT. IL-32γ suppressed atopic dermatitis through inhibition of miR-205 expression via inactivation of nuclear factor-kappa B. Journal of Allergy and Clinical Immunology 2020;146:156-68. [DOI: 10.1016/j.jaci.2019.12.905] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
28 Bak Y, Kwon T, Bak IS, Hong J, Yu DY, Yoon DY. IL-32θ inhibits stemness and epithelial-mesenchymal transition of cancer stem cells via the STAT3 pathway in colon cancer. Oncotarget. 2016;7:7307-7317. [PMID: 26824417 DOI: 10.18632/oncotarget.7007] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 4.5] [Reference Citation Analysis]
29 Diakowska D, Krzystek-Korpacka M. Local and Systemic Interleukin-32 in Esophageal, Gastric, and Colorectal Cancers: Clinical and Diagnostic Significance. Diagnostics (Basel) 2020;10:E785. [PMID: 33020452 DOI: 10.3390/diagnostics10100785] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
30 Bhat S, Gardi N, Hake S, Kotian N, Sawant S, Kannan S, Parmar V, Desai S, Dutt A, Joshi NN. Impact of intra-tumoral IL17A and IL32 gene expression on T-cell responses and lymph node status in breast cancer patients. J Cancer Res Clin Oncol 2017;143:1745-56. [PMID: 28470472 DOI: 10.1007/s00432-017-2431-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
31 Son DJ, Jung YY, Seo YS, Park H, Lee DH, Kim S, Roh YS, Han SB, Yoon DY, Hong JT. Interleukin-32α Inhibits Endothelial Inflammation, Vascular Smooth Muscle Cell Activation, and Atherosclerosis by Upregulating Timp3 and Reck through suppressing microRNA-205 Biogenesis. Theranostics 2017;7:2186-203. [PMID: 28740544 DOI: 10.7150/thno.18407] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 5.6] [Reference Citation Analysis]
32 Yun HM, Park KR, Kim EC, Han SB, Yoon DY, Hong JT. IL-32α suppresses colorectal cancer development via TNFR1-mediated death signaling. Oncotarget 2015;6:9061-72. [PMID: 25909160 DOI: 10.18632/oncotarget.3197] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 3.2] [Reference Citation Analysis]
33 Testi S, Azzarà A, Giovannini C, Lombardi S, Piaggi S, Facioni MS, Scarpato R. Vincristine-induced bystander effect in human lymphocytes. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis 2016;789:39-47. [DOI: 10.1016/j.mrfmmm.2016.03.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
34 Heinhuis B, Plantinga TS, Semango G, Küsters B, Netea MG, Dinarello CA, Smit JW, Netea-maier RT, Joosten LA. Alternatively spliced isoforms of IL-32 differentially influence cell death pathways in cancer cell lines. CARCIN 2016;37:197-205. [DOI: 10.1093/carcin/bgv172] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 4.7] [Reference Citation Analysis]
35 Chakma K, Gu Z, Abudurexiti Y, Hata T, Motoi F, Unno M, Horii A, Fukushige S. Epigenetic inactivation of IRX4 is responsible for acceleration of cell growth in human pancreatic cancer. Cancer Sci 2020;111:4594-604. [PMID: 32894817 DOI: 10.1111/cas.14644] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
36 Hong JT, Son DJ, Lee CK, Yoon DY, Lee DH, Park MH. Interleukin 32, inflammation and cancer. Pharmacol Ther. 2017;174:127-137. [PMID: 28223235 DOI: 10.1016/j.pharmthera.2017.02.025] [Cited by in Crossref: 54] [Cited by in F6Publishing: 63] [Article Influence: 10.8] [Reference Citation Analysis]
37 Messina NL, Banks KM, Vidacs E, Martin BP, Long F, Christiansen AJ, Smyth MJ, Clarke CJP, Johnstone RW. Modulation of antitumour immune responses by intratumoural Stat1 expression. Immunol Cell Biol 2013;91:556-67. [DOI: 10.1038/icb.2013.41] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
38 Choi SY, Ryu J, You D, Jeong IG, Hong JH, Ahn H, Kim CS. Prognostic factors of oncologic outcomes in metastatic chemotherapy-naïve castration-resistant prostate cancer treated with enzalutamide in actual clinical practice in East Asia. Urol Oncol 2018;36:401.e11-8. [PMID: 30274641 DOI: 10.1016/j.urolonc.2018.06.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
39 Kang JY, Kim KE. Prognostic Value of Interleukin-32 Expression and Its Correlation with the Infiltration of Natural Killer Cells in Cutaneous Melanoma. J Clin Med 2021;10:4691. [PMID: 34682815 DOI: 10.3390/jcm10204691] [Reference Citation Analysis]